Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

Development of Flame-Retarded Nanocomposites from Recycled PET Bottles for the Electronics Industry.

Ronkay F, Molnár B, Szalay F, Nagy D, Bodzay B, Sajó IE, Bocz K.

Polymers (Basel). 2019 Feb 1;11(2). pii: E233. doi: 10.3390/polym11020233.

2.

Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease.

Ferenci P, Stremmel W, Członkowska A, Szalay F, Viveiros A, Stättermayer AF, Bruha R, Houwen R, Pop TL, Stauber R, Gschwantler M, Pfeiffenberger J, Yurdaydin C, Aigner E, Steindl-Munda P, Dienes HP, Zoller H, Weiss KH.

Hepatology. 2019 Apr;69(4):1464-1476. doi: 10.1002/hep.30280. Epub 2019 Mar 1.

PMID:
30232804
3.

Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy.

Hunyady B, Abonyi M, Gerlei Z, Gervain J, Horváth G, Jancsik V, Lengyel G, Makkai E, Pár A, Péter Z, Pusztay M, Ribiczey P, Rókusz L, Sarrazin C, Schneider F, Susser S, Szalay F, Tornai I, Tusnádi A, Újhelyi E, Werling K, Makara M.

Clin Exp Hepatol. 2018 Jun;4(2):83-90. doi: 10.5114/ceh.2018.75957. Epub 2018 May 25.

4.

[Diagnosis and treatment of chronic hepatitis B and D. National consensus guideline in Hungary from 22 September 2017].

Horváth G, Gerlei Z, Gervain J, Lengyel G, Makara M, Pár A, Rókusz L, Szalay F, Tornai I, Werling K, Hunyady B.

Orv Hetil. 2018 Feb;159(Suppl 1):24-37. doi: 10.1556/650.2018.31004. Hungarian.

PMID:
29478340
5.

[Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 22 September 2017].

Hunyady B, Gerlei Z, Gervain J, Horváth G, Lengyel G, Pár A, Péter Z, Rókusz L, Schneider F, Szalay F, Tornai I, Werling K, Makara M.

Orv Hetil. 2018 Feb;159(Suppl 1):3-23. doi: 10.1556/650.2018.31003. Hungarian.

PMID:
29478339
6.

Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.

Tornai T, Tornai D, Sipeki N, Tornai I, Alsulaimani R, Fechner K, Roggenbuck D, Norman GL, Veres G, Par G, Par A, Szalay F, Lakatos PL, Antal-Szalmas P, Papp M.

Sci Rep. 2018 Jan 10;8(1):399. doi: 10.1038/s41598-017-18622-1.

7.

Cholangiocarcinoma in Wilson's Disease - a Case Report.

Németh D, Folhoffer A, Smuk G, Kajtár B, Tornóczky T, Szalay F.

J Gastrointestin Liver Dis. 2017 Sep;26(3):305-308. doi: 10.15403/jgld.2014.1121.263.nem.

8.

Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.

Tornai T, Palyu E, Vitalis Z, Tornai I, Tornai D, Antal-Szalmas P, Norman GL, Shums Z, Veres G, Dezsofi A, Par G, Par A, Orosz P, Szalay F, Lakatos PL, Papp M.

World J Gastroenterol. 2017 Aug 7;23(29):5412-5421. doi: 10.3748/wjg.v23.i29.5412.

9.

Diurnal variation of the melanin-concentrating hormone level in the hypothalamus.

Gerics B, Szalay F, Sótonyi P, Jancsik V.

Acta Biol Hung. 2017 Mar;68(1):14-21. doi: 10.1556/018.68.2017.1.2.

PMID:
28322083
10.

[Diagnosis and treatment of chronic hepatitis B and D. National consensus guideline in Hungary from 15 October 2016].

Horváth G, Gerlei Z, Gervain J, Lengyel G, Makara M, Pár A, Rókusz L, Szalay F, Tornai I, Werling K, Hunyady B.

Orv Hetil. 2017 Feb;158(Suppl 1):23-35. doi: 10.1556/650.2017.30689. Hungarian.

PMID:
28218868
11.

[Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 15 October 2016].

Hunyady B, Gerlei Z, Gervain J, Horváth G, Lengyel G, Pár A, Péter Z, Rókusz L, Schneider F, Szalay F, Tornai I, Werling K, Makara M.

Orv Hetil. 2017 Feb;158(Suppl 1):3-22. doi: 10.1556/650.2017.30688. Hungarian.

PMID:
28218867
12.

Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.

Hézode C, Almasio PL, Bourgeois S, Buggisch P, Brown A, Diago M, Horsmans Y, Serfaty L, Szalay F, Gaeta GB, Planas R, Schlag M, Lonjon-Domanec I, Omoruyi E, DeMasi R, Zeuzem S.

Liver Int. 2017 Sep;37(9):1304-1313. doi: 10.1111/liv.13376. Epub 2017 Mar 13.

PMID:
28135777
13.

[Vitamin D metabolism and signaling in human hepatocellular carcinoma and surrounding non-tumorous liver].

Horváth E, Balla B, Kósa J, Lakatos PA, Lazáry Á, Németh D, Jozilan H, Somorácz Á, Korompay A, Gyöngyösi B, Borka K, Kiss A, Kupcsulik P, Schaff Z, Szalay F.

Orv Hetil. 2016 Nov;157(48):1910-1918. Hungarian.

PMID:
27889974
14.

[Efficacy and safety of boceprevir based triple therapy in Hungarian patients with hepatitis C genotype 1 infection, advanced stage fibrosis and prior treatment failure].

Hunyady B, Abonyi M, Csefkó K, Gervain J, Haragh A, Horváth G, Jancsik V, Makkai E, Müller Z, Ribiczey P, Sipos B, Szabó O, Szalay F, Szentgyörgyi L, Tornai I, Újhelyi E, Varga M, Weisz G, Makara M.

Orv Hetil. 2016 Aug;157(34):1366-74. doi: 10.1556/650.2016.30538. Hungarian.

PMID:
27546804
15.

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.

Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S, Bakalos G, Hassanein T; GUARD-C Study Group.

PLoS One. 2016 Mar 28;11(3):e0151703. doi: 10.1371/journal.pone.0151703. eCollection 2016.

16.

Clinical Use of Next-Generation Sequencing in the Diagnosis of Wilson's Disease.

Németh D, Árvai K, Horváth P, Kósa JP, Tobiás B, Balla B, Folhoffer A, Krolopp A, Lakatos PA, Szalay F.

Gastroenterol Res Pract. 2016;2016:4548039. doi: 10.1155/2016/4548039. Epub 2015 Dec 24.

17.

A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től.

Horváth G, Gerlei Z, Gervain J, Lengyel G, Makara M, Pár A, Rókusz L, Szalay F, Tornai I, Werling K, Hunyady B.

Orv Hetil. 2015 Dec 15;156 Suppl 2:25-36. doi: 10.1556/OH.2015.30331. Hungarian.

PMID:
26667112
18.

Hepatitis C-vírus-fertőzés: diagnosztika, antivirális terápia, kezelés utáni gondozás. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től.

Hunyady B, Gerlei Z, Gervain J, Horváth G, Lengyel G, Pár A, Péter Z, Rókusz L, Schneider F, Szalay F, Tornai I, Werling K, Makara M.

Orv Hetil. 2015 Dec 15;156 Suppl 2:3-24. doi: 10.1556/OH.2015.30345. Hungarian.

PMID:
26667111
19.

Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).

Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV; ESSENTIAL II Study Group.

Aliment Pharmacol Ther. 2015 Oct;42(7):829-44. doi: 10.1111/apt.13342. Epub 2015 Aug 4.

20.

Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline.

Horváth G, Gerlei Z, Gervain J, Lengyel G, Makara M, Pár A, Rókusz L, Szalay F, Telegdy L, Tornai I, Werling K, Hunyady B.

Orv Hetil. 2015 Mar;156 Suppl 1:25-35. doi: 10.1556/OH.2015.30071. Hungarian.

PMID:
26039414

Supplemental Content

Loading ...
Support Center